tiprankstipranks
Advertisement
Advertisement

NL:PHARM Stock Latest News

Pharming announces approval of Joenja in Japan for patients aged 4 years and old
The FlyPharming announces approval of Joenja in Japan for patients aged 4 years and old
5d ago
PHAR
Pharming price target lowered to $41 from $42 at Oppenheimer
PremiumThe Fly
Pharming price target lowered to $41 from $42 at Oppenheimer
16d ago
PHAR
Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
PremiumRatings
Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
17d ago
PHAR
Is PHGUF a Buy, Before Earnings?
PremiumPre-Earnings
Is PHGUF a Buy, Before Earnings?
19d ago
Morning Movers: Disney dips following fourth quarter earnings
PremiumThe Fly
Morning Movers: Disney dips following fourth quarter earnings
2M ago
DIS
DVN
Pharming to host virtual investor day
PremiumThe FlyPharming to host virtual investor day
2M ago
PHAR
Pharming Hit by FDA Setback on Joenja Pediatric Expansion but Adult Approval Unaffected
Premium
Company Announcements
Pharming Hit by FDA Setback on Joenja Pediatric Expansion but Adult Approval Unaffected
2M ago
Pharming receives CRL from U.S. FDA for sNDA for Joenja
Premium
The Fly
Pharming receives CRL from U.S. FDA for sNDA for Joenja
2M ago
PHAR
Pharming price target raised to $42 from $41 at Oppenheimer
PremiumThe Fly
Pharming price target raised to $42 from $41 at Oppenheimer
5M ago
PHAR
Pharming Group Reports Strong Q3 2025 Growth
PremiumCompany Announcements
Pharming Group Reports Strong Q3 2025 Growth
5M ago
Pharming Group N.V. Reports Strong Q3 2025 Earnings
PremiumCompany Announcements
Pharming Group N.V. Reports Strong Q3 2025 Earnings
5M ago
PHGUF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
PHGUF Upcoming Earnings Report: What to Expect?
5M ago
Pharming announces 20% net reduction in non-commercial, non-medical headcount
PremiumThe FlyPharming announces 20% net reduction in non-commercial, non-medical headcount
6M ago
PHAR
Pharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential
Premium
Ratings
Pharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential
6M ago
PHAR
= Pharming Group NV ADS trading resumes
Premium
The Fly
= Pharming Group NV ADS trading resumes
8M ago
PHAR
= Pharming Group NV ADS trading halted, volatility trading pause
PremiumThe Fly
= Pharming Group NV ADS trading halted, volatility trading pause
8M ago
PHAR
Pharming price target raised to EUR 2.45 from EUR 2 at RBC Capital
PremiumThe Fly
Pharming price target raised to EUR 2.45 from EUR 2 at RBC Capital
8M ago
PHAR
Pharming Group N.V. Reports Strong Q2 Earnings
PremiumCompany Announcements
Pharming Group N.V. Reports Strong Q2 Earnings
8M ago
Pharming price target raised to $41 from $40 at Oppenheimer
PremiumThe Fly
Pharming price target raised to $41 from $40 at Oppenheimer
8M ago
PHAR
Pharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating
PremiumRatingsPharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating
8M ago
PHAR
Pharming Group Reports Strong Revenue Growth in 2025
Premium
Company Announcements
Pharming Group Reports Strong Revenue Growth in 2025
8M ago
Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment
Premium
Ratings
Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment
9M ago
PHAR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >